F
Finn Burg
Researcher at Technische Universität München
Publications - 8
Citations - 239
Finn Burg is an academic researcher from Technische Universität München. The author has contributed to research in topics: Enantioselective synthesis & Catalysis. The author has an hindex of 5, co-authored 7 publications receiving 150 citations. Previous affiliations of Finn Burg include Center for Integrated Protein Science Munich.
Papers
More filters
Journal ArticleDOI
Site- and Enantioselective C-H Oxygenation Catalyzed by a Chiral Manganese Porphyrin Complex with a Remote Binding Site.
TL;DR: Mechanistic studies support the hypothesis that the reaction proceeds through a rate- and selectivity-determining attack of the reactive manganese oxo complex at the hydrogen-bound substrate and an oxygen transfer by a rebound mechanism.
Journal ArticleDOI
Lactam Hydrogen Bonds as Control Elements in Enantioselective Transition-Metal-Catalyzed and Photochemical Reactions.
Finn Burg,Thorsten Bach +1 more
TL;DR: In the last two decades, hydrogen bonds have been established as useful interactions to control the selectivity of various chemical transformations and catalysts have been developed which combine, in an enzyme-like fashion, a site for substrate binding and a catalytically active site.
Journal ArticleDOI
Enantioselective oxygenation of exocyclic methylene groups by a manganese porphyrin catalyst with a chiral recognition site.
TL;DR: In this article, a biomimetic hydroxylation approach was proposed to catalyse highly selective oxygen insertion reactions into unactivated C-H bonds under mild conditions, where the site-selectivity was completely altered in favour of a less reactive but more accessible position.
Journal ArticleDOI
A (+)-Larixol Congener with High Affinity and Subtype Selectivity toward TRPC6.
Stephanie Häfner,Finn Burg,Martina Kannler,Nicole Urban,Peter Mayer,Alexander Dietrich,Dirk Trauner,Dirk Trauner,Johannes Broichhagen,Johannes Broichhagen,Michael Schaefer +10 more
TL;DR: Treatment of isolated perfused lung preparations with SH045 led to a decrease in lung ischemia‐reperfusion edema (LIRE) and a TRPC6 blocker that holds promise for the translational treatment of LIRE is reported.